Public health data show rising COVID-19 activity during the back-to-school period, even as overall respiratory illness remains relatively low, with cases increasing across most states by late August.

Wastewater surveillance signals very high virus levels in Texas and elevated levels in Mississippi, underscoring community transmission alongside clinical data.

The FDA has approved a new vaccine tailored for adults 65 and older and for children with high-risk conditions, expanding protection options.

Vaccination eligibility guidance specifies different vaccines by age and risk: Spikevax (6 months+), Pfizer-BioNTech (5+), mNexspike (12+), and Novavax (12+).

Vaccinated individuals with symptoms should stay home and contact a healthcare provider promptly, since treatments are most effective when started within the first five days.

The report relies on interviews with Dr. Jason Bowling and situates the news in the context of vaccine approvals, preventive options, and the potential overlap of flu and COVID seasons.

The broader context includes related health news and ongoing vaccine availability updates as reported by Today and AP.

Boone County plans to receive vaccine shipments in late September to improve access to prevention measures.

Medical guidance emphasizes at-home symptom management with fluids, proper nutrition, and fever reducers, alongside hand-washing and masking where appropriate; there is no fixed quarantine period for returning to school.

Seek emergency care for extreme shortness of breath or inability to keep fluids down; otherwise monitor symptoms and use fever-free period (about 24 hours) as a guide before sending children back to school.

Vaccination is emphasized for students to reduce risk, as infections can be asymptomatic in younger people while vulnerable individuals may suffer more severe outcomes.

A new post-exposure prevention option, incetrovir (Zocova), is available and can reduce the risk when taken within three days of exposure; the course lasts five days.